Increased survival time of a patient with metastatic malignant melanoma following immunotherapy: A case report and literature review

Zhang,Yong; Song,Yongping; Gao,Quanli

doi:10.3892/ol.2015.3296

Increased survival time of a patient with metastatic malignant melanoma following immunotherapy: A case report and literature review

Authors:
- Yong Zhang
- Yongping Song
- Quanli Gao
View Affiliations

Affiliations: Department of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450003, P.R. China
Published online on: May 29, 2015 https://doi.org/10.3892/ol.2015.3296
Pages: 883-886

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metastatic malignant melanoma is treated with chemotherapy and radiotherapy. A number of previous studies have indicated that cytokine‑induced killer cells (CIK cells) are a heterogeneous cell population that express cluster of differentiation (CD)3 and CD56, in addition to the natural killer cell NKG2D activating receptor. CIK cells possess major histocompatibility complex‑unrestricted cytotoxicity towards cancer, but not towards normal targets. The present study investigated whether the addition of CIK cells resulted in an improved therapeutic response in a patient with metastatic malignant melanoma. In the current case, a patient with metastatic malignant melanoma received CIK therapy, which resulted in a relatively long survival time of 28 months. To the best of our knowledge, there have been no previous studies reporting such positive effects in a patient who received CIK cell immunotherapy. Based on the findings of the present study, CIK cell therapy may be an option that results in a good prognosis in certain patients with metastatic malignant melanoma.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
2	Ghosh P and Chin L: Genetics and genomics of melanoma. Expert Rev Dermatol. 4:1312009. View Article : Google Scholar : PubMed/NCBI
3	Balch CM, Soong SJ, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 19:3622–3634. 2001.PubMed/NCBI
4	Barth A, Wanek LA and Morton DL: Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 181:193–201. 1995.PubMed/NCBI
5	Hontscha C, Borck Y, Zhou H, Messmer D and Schmidt-Wolf IG: Clinical trials on CIK cells: First report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 137:305–310. 2011. View Article : Google Scholar : PubMed/NCBI
6	Schwaab T, Schwarzer A, Wolf B, et al: Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res. 15:4986–4992. 2009. View Article : Google Scholar : PubMed/NCBI
7	Rosenberg SA, Spiess P and Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 233:1318–1321. 1986. View Article : Google Scholar : PubMed/NCBI
8	Rosenberg S: Lymphokine-activated killer cells: A new approach to immunotherapy of cancer. J Natl Cancer Inst. 75:595–603. 1985.PubMed/NCBI
9	Yun YS, Hargrove ME and Ting CC: In vivo antitumor activity of anti-CD3-induced activated killer cells. Cancer Res. 49:4770–4774. 1989.PubMed/NCBI
10	Shablak A, Hawkins RE, Rothwell DG and Elkord E: T cell-based immunotherapy of metastatic renal cell carcinoma: Modest success and future perspective. Clin Cancer Res. 15:6503–6510. 2009. View Article : Google Scholar : PubMed/NCBI
11	Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG and Weissman IL: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 174:139–149. 1991. View Article : Google Scholar : PubMed/NCBI
12	Li R, Wang C, Liu L, et al: Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother. 61:2125–2133. 2012. View Article : Google Scholar : PubMed/NCBI
13	Shi L, Zhou Q, Wu J, et al: Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother. 61:2251–2259. 2012. View Article : Google Scholar : PubMed/NCBI
14	Liu L, Zhang W, Qi X, et al: Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res. 18:1751–1759. 2012. View Article : Google Scholar : PubMed/NCBI
15	Hersey P: Immunotherapy of melanoma. Asia Pac J Clin Oncol. 6 Suppl:1:S2–S8. 2010. View Article : Google Scholar
16	Schmidt-Wolf IG, Finke S, Trojaneck B, et al: Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer. 81:1009–1016. 1999. View Article : Google Scholar : PubMed/NCBI
17	Jiang J, Xu N, Wu C, et al: Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res. 26 (3B):2237–2242. 2006.PubMed/NCBI
18	Wu C, Jiang J, Shi L and Xu N: Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res. 28 (6B):3997–4002. 2008.PubMed/NCBI
19	Hui D, Qiang L, Jian W, Ti Z and Da-Lu K: A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis. 41:36–41. 2009. View Article : Google Scholar : PubMed/NCBI
20	Li W, Xu LP, DI Zhao L, et al: Cytokine-induced killer cell therapy for advanced pancreatic adenocarcinoma: A case report and review of the literature. Oncol Lett. 5:1427–1429. 2013.PubMed/NCBI
21	Huang ZM, Li W, Li S, et al: Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients. J Immunother. 36:287–293. 2013. View Article : Google Scholar : PubMed/NCBI
22	Alexandrescu DT, Ichim TE, Riordan NH, et al: Immunotherapy for melanoma: Current status and perspectives. J Immunother. 33:570–590. 2010. View Article : Google Scholar : PubMed/NCBI
23	Robert C, Long GV, Brady B, et al: Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 372:320–330. 2015. View Article : Google Scholar : PubMed/NCBI
24	Zhao Q, Zhang H, Li Y, Liu J, Hu X and Fan L: Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro. J Exp Clin Cancer Res. 29:1182010. View Article : Google Scholar : PubMed/NCBI
25	Wang FS, Liu MX, Zhang B, et al: Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. World J Gastroenterol. 8:464–468. 2002.PubMed/NCBI
26	Zhang YS, Yuan FJ, Jia GF, et al: CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R. World J Gastroenterol. 11:3339–3345. 2005. View Article : Google Scholar : PubMed/NCBI
27	Karimi M, Cao TM, Baker JA, Verneris MR, Soares L and Negrin RS: Silencing human NKG2D, DAP10 and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. J Immunol. 175:7819–7828. 2005. View Article : Google Scholar : PubMed/NCBI
28	Verneris MR, Karami M, Baker J, Jayaswal A and Negrin RS: Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood. 103:3065–3072. 2004. View Article : Google Scholar : PubMed/NCBI
29	Schmidt-Wolf IG, Lefterova P, Mehta BA, et al: Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol. 21:1673–1679. 1993.PubMed/NCBI
30	Joshi PS, Liu JQ, Wang Y, et al: Cytokine-induced killer T cells kill immature dendritic cells by TCR-independent and perforin-dependent mechanisms. J Leukoc Biol. 80:1345–1353. 2006. View Article : Google Scholar : PubMed/NCBI
31	Gammaitoni L, Giraudo L, Leuci V, et al: Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features. Clin Cancer Res. 19:4347–4358. 2013. View Article : Google Scholar : PubMed/NCBI